Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting

- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO...
April 20, 2026 09:00 ET | Source: Immuneering Corporation

Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond

Analysis of circulating tumor DNA from atebimetinib-treated patients shows acquired MAPK pathway alterations are rare, supporting observed durable first-line activity Atebimetinib-treated tumors...
April 06, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference

Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
March 06, 2026 07:45 ET | Source: Immuneering Corporation

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 02, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present at the Leerink Global Healthcare Conference

Immuneering to Present at the Leerink Global Healthcare Conference
February 18, 2026 16:05 ET | Source: Immuneering Corporation

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
January 07, 2026 16:00 ET | Source: Immuneering Corporation

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
December 23, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026

Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu
December 17, 2025 16:05 ET | Source: Immuneering Corporation

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA

Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA
December 16, 2025 08:00 ET | Source: Immuneering Corporation

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)

Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)